P696: SUBTHERAPEUTIC TKI DOSES FOR THE MAINTENANCE OF CML PATIENTS WITH INTOLERANCE OR REFUSAL TO DISCONTINUE: A SINGLE CENTER FEASIBILITY STUDY.

P696: SUBTHERAPEUTIC TKI DOSES FOR THE MAINTENANCE OF CML PATIENTS WITH INTOLERANCE OR REFUSAL TO DISCONTINUE: A SINGLE CENTER FEASIBILITY STUDY.

Bibliographic Details
Main Authors:	A. Borrero, A. Segura, S. Sanchez, R. Stuckey, J. F. López, C. Bilbao, M. T. Gomez casares
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845668.52210.0f

Similar Items

Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice
by: Yilin Chen, et al.
Published: (2023-01-01)

Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19
by: Chengxin Luan, et al.
Published: (2022-06-01)

Blast Crisis of CML After TKI Discontinuation in a Patient With Previous Stable Deep Molecular Response: Is It Safe to Stop?
by: Apostolia Papalexandri, et al.
Published: (2018-12-01)

Injudicious Provision of Subtherapeutic Doses of Antibiotics in Community Pharmacies
by: Mohamed E Amin, et al.
Published: (2017-02-01)

Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
by: Cutica I, et al.
Published: (2022-10-01)

Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance
by: Jusuf Imeri, et al.
Published: (2023-03-01)

Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models
by: Fabien Muselli, et al.
Published: (2021-04-01)

Efficacy of nilotinib therapy in patient with CML diagnosed in pre-TKI era and resistant to imatinib
by: Ivana Pierri, et al.
Published: (2015-10-01)

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

S157: BCR::ABL1 DIGITAL PCR IDENTIFIES CHRONIC PHASE CML PATIENTS SUITABLE FOR AN EARLY TKI DISCONTINUATION ATTEMPT: A PATIENT-LEVEL META-ANALYSIS
by: C. Kockerols, et al.
Published: (2022-06-01)

Variable behavior of iPSCs derived from CML patients for response to TKI and hematopoietic differentiation.
by: Aurélie Bedel, et al.
Published: (2013-01-01)

Evaluation of CML TKI Induced Cardiovascular Toxicity and Development of Potential Rescue Strategies in a Zebrafish Model
by: Shan Cheng, et al.
Published: (2021-10-01)

Recurrent tuberculosis due to subtherapeutic levels of antitubercular treatment
by: A Kirubanandam, et al.
Published: (2020-01-01)

Alternative approaches to therapeutics and subtherapeutics for sustainable poultry production
by: Zajeba Tabashsum, et al.
Published: (2023-07-01)

P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE
by: Lukas Semerad, et al.
Published: (2023-08-01)

Bacteriophages Combined With Subtherapeutic Doses of Flucloxacillin Act Synergistically Against Staphylococcus aureus Experimental Infective Endocarditis
by: Jonathan Save, et al.
Published: (2022-02-01)

Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib
by: Emilio Usala
Published: (2015-10-01)

PVR and ICAM-1 on Blast Crisis CML Stem and Progenitor Cells with TKI Resistance Confer Susceptibility to NK Cells
by: Nayoung Kim, et al.
Published: (2020-07-01)

Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients
by: Alexander V. Lavrov, et al.
Published: (2019-03-01)

Differential Impact of Subtherapeutic Antibiotics and Ionophores on Intestinal Microbiota of Broilers
by: Kelsy Robinson, et al.
Published: (2019-08-01)

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
by: Simona Bernardi, et al.
Published: (2019-05-01)

Interfacing to S-100/IEEE 696 microcomputers/
by: 395401 Libes, Sol, et al.
Published: (1981)

Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia
by: Yilin Chen, et al.
Published: (2023-08-01)

P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL
by: Philipp Le Coutre, et al.
Published: (2023-08-01)

Subtherapeutic Doses of Vancomycin Synergize with Bacteriophages for Treatment of Experimental Methicillin-Resistant <i>Staphylococcus aureus</i> Infective Endocarditis
by: Jonathan Save, et al.
Published: (2022-08-01)

Increased dosing regimens of piperacillin-tazobactam are needed to avoid subtherapeutic exposure in critically ill patients with augmented renal clearance
by: Thibaud Besnard, et al.
Published: (2019-01-01)

Steering Away from Current Amoxicillin Dose Reductions in Hospitalized Patients with Impaired Kidney Function to Avoid Subtherapeutic Drug Exposure
by: Cornelis Smit, et al.
Published: (2022-09-01)

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
by: Arne Carlsen, et al.
Published: (2018-03-01)

Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
by: Lydia Ntari, et al.
Published: (2021-04-01)

New dosing schedules of dasatinib for CML and adverse event management
by: Wong Siu-Fun
Published: (2009-02-01)

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
by: Frédéric Millot, et al.
Published: (2021-08-01)

Subtherapeutic Kitasamycin Promoted Fat Accumulation in the Longissimus Dorsi Muscle in Growing–Finishing Pigs
by: Ge Han, et al.
Published: (2024-03-01)

TKI
by: Dayat Hidayat
Published: (2020-03-01)

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal
by: Carolina Pavlovsky, et al.
Published: (2023-04-01)

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
by: A. Iurlo, et al.
Published: (2023-03-01)

BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC”
by: Sara Di Giusto, et al.
Published: (2023-02-01)

P4.45 SUBTHERAPEUTIC, LOW-DOSE FLUVASTATIN IMPROVES FUNCTIONAL AND MORPHOLOGICAL ARTERIAL WALL PROPERTIES IN APPARENTLY HEALTHY, MIDDLE-AGED MALES
by: M. Lunder, et al.
Published: (2012-11-01)

10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN A SINGLE UK CENTRE: COMPARISON WITH PRE-TKI ERA AND EVALUATION OF 2013 ELN GUIDELINES
by: Khan, D, et al.
Published: (2014)

P708: CANADIAN AND RUSSIAN EXPERIENCES OF ASCIMINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WHO FAILED MULTIPLE LINES OF TYROSINE KINASE INHIBITOR (TKI) THERAPY.
by: F. Khadadah, et al.
Published: (2022-06-01)

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML
by: Mathias Schneeweiss-Gleixner, et al.
Published: (2019-12-01)